Why OKUR Stock Traded Steady Today — RQD Quant Desk Flash

Per the Roarable RQD rating, OKUR scores 46 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 7 / 20 (ROIC -35%; FCF yield 0%). This is the weakest pillar and reflects negative returns on invested capital and no free-cash-flow yield.
• Whale 13F Flow: 9 / 20 (institutional accumulation and options positioning). Below mid-range, indicating limited institutional tailwind in the rating's view.
• Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). The lowest sub-score on the rating, signaling weak insider-side conviction.
• Macro Regime Fit: 15 / 20 (Beta 1.0; sector sensitivity). A moderate score, reflecting a market-neutral beta profile.
• Forensic Balance Sheet: 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Mid-to-low, with a weak Piotroski reading.

For a prospective investor, the rating's message is that the upside case rests on a pre-revenue pipeline funded by cash on hand, not on current cash generation. Operating losses and negative ROIC mean value must come from future events rather than present earnings. Upside drivers would be clinical or regulatory progress that the supplied data does not describe. Valuation tradeoffs are substantial: with no reported EPS or P/E, the stock cannot be benchmarked on earnings. The 0% FCF yield and the sharp decline in reported cash (from $110.8M in FY 2024 to $59.0M in FY 2025) imply that further capital raises or cost reductions may be needed, which can dilute existing holders. The rating's distribution warning and low insider-conviction score point to weak support from insiders. This brief is educational and does not constitute personalized financial advice.

Per the SEC financials, operating losses widened from $-36.9M in FY 2023 to $-63.0M in FY 2025, and net losses followed the same path. Gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating. Debt/Equity is 0.5. Reported cash fell from $110.8M to $59.0M over FY 2024 to FY 2025.

Per the recent news feed, the items relate to OKUR and carry the following labels:

• A TradingView item (YELLOW, MARKET WIRE) references a Q3'26 earnings revenue estimate of 166.67K USD.
• A Benzinga item (GREEN, CATALYST) headlines "Alpha Buying" in beaten-down biotech stocks backed by a specialist investor.
• A Seeking Alpha item (RED, RISK WATCH) references an estimated Russell 2000 deletion of 83 stocks in the December rebalance.
• A TradingKey item (GREEN, CATALYST) lists OKUR among top U.S. stock gainers.
• A siam.in item (YELLOW, MARKET WIRE) concerns a different issuer, Tenax Therapeutics (TENX), and is not OKUR-specific.
• A dars.gov.et item (RED, RISK WATCH) concerns MAX Q2 2026 earnings, an issuer not identified as OKUR, and is not OKUR-specific.

The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What are OnKure's products, pipeline stage, and expected regulatory or clinical milestones?
• What is the company's cash runway given reported cash of $59.0M at FY 2025 and negative FCF of $-51.9M?
• Does the company plan equity raises that could dilute shareholders?
• What drove the year-over-year increase in operating loss from $-54.4M to $-63.0M?
• Who are the institutional holders and what are the sizes of their positions?